Pharmaceutical Contract Manufacturing Market Analysis North America, Asia, Europe, Rest of World (ROW) - US, Germany, UK, China, India - Size and Forecast 2023-2027

Published: Oct 2023 Pages: 159 SKU: IRTNTR75122

The pharmaceutical contract manufacturing market size is estimated to grow at a CAGR of 7.81% between 2022 and 2027. The pharmaceutical contract manufacturing market size is forecast to increase by USD 58 billion. The growth of the market depends on several factors, including the patent expiry and increasing demand for generic drugs, the growing need to focus on core competencies, and the strong research funding.

This pharmaceutical contract manufacturing market report extensively covers market segmentation by end-user (big pharmaceutical companies, small and medium-sized pharmaceutical companies, and generic pharmaceutical companies), service (api/bulk drug manufacturing, final dosage form, and secondary packaging), and geography (North America, Asia, Europe, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

What will be the Size of the Pharmaceutical Contract Manufacturing Market During the Forecast Period?

To learn more about this report, View Report Sample

Pharmaceutical Contract Manufacturing Market: Key Drivers, Trends, Challenges, and Customer Landscape

The patent expiry and increasing demand for generic drugs are notably driving the market growth, although factors such as the capacity utilization and constraints may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key Pharmaceutical Contract Manufacturing Market Driver

Patent expiry and increasing demand for generic drugs is the key factor driving the growth of the global pharmaceutical contract manufacturing market. Generic drugs are cheaper medicines with the same therapeutic safety and efficacy as the branded version. One of the main reasons for the expansion of the generic drug industry is the increasing pressure to reduce rising healthcare costs. With such cost savings in mind, governments around the world are encouraging the use of generic drugs. Expiration of various pharmaceutical patents is another important reason behind the expansion of the generic drug industry. In emerging nations such as South Korea, around 51 patents covering more than 150 pharmaceutical products are scheduled for termination in 2023.

Although the patent cliff has resulted in significant income and volume losses for the branded drug industry, patent expiration allows multiple cheaper generic equivalents to enter the market (which will boost the volume of drugs sold). This is a positive indication for industry expansion because generics companies outsource around 80% of their production to CDMOs. These factors are expected to drive the growth of the market during the forecast period.

Significant Pharmaceutical Contract Manufacturing Market Trends

One of the recent trends in the global contract manufacturing market is the increase in US FDA-approved manufacturing facilities in emerging markets. China and India are two key countries in the global contract manufacturing market. China's contract pharmaceutical manufacturing market has been limited to Contract Research Organizations (CROs) due to strict government regulations on CMOs. However, the market has witnessed a significant change since the country's State Council allowed drug Marketing Authorization Holders (MAH) to use third-party licensed manufacturers or CMOs in most regions of the country.

As a result, the market has witnessed an increase in the number of US FDA-approved facilities in the country. Various foreign pharmaceutical companies are outsourcing the manufacture of drugs to CMOs in the country, which is increasing the adoption of CMOs. Thus, an increasing number of US FDA-approved manufacturing facilities will drive the growth of the market during the forecast period.

Major Pharmaceutical Contract Manufacturing Market Challenge

Capacity utilization and constraints are major challenges to the growth of the global pharmaceutical contract manufacturing market. Utilization is a measure of actual production versus potential production at the company's maximum production capacity. Due to the complexity of the manufacturing process, it plays an important role in the production of various therapeutic agents, especially biological medicines. Approximately 35% of CMOs face minor constraints such as time, cost and resources at least at some stage of the manufacturing process, and an estimated 20% of CMOs face moderate to severe constraints during the manufacturing process. Such constraints associated with manufacturing are preventing CMOs from producing therapeutics at their full potential, which is causing delays in the launch of several therapeutics.

Additionally, the high cost of downstream cleaning further impedes CMOs from operating at optimal capacity. Factors such as the limited number of approved production sites also lead to capacity bottlenecks. Lack of new and experienced scientists, technical personnel, and production personnel. Lack of cheap disposable products. The limitations of advanced cell culture systems on upstream performance are also causing limitations in the market. Therefore, the above factors are expected to hinder the growth of the focus market during the forecast period.

Key Pharmaceutical Contract Manufacturing Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Pharmaceutical Contract Manufacturing Market Customer Landscape

Who are the Major Pharmaceutical Contract Manufacturing Market Vendors?

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

Almac Group Ltd.: The company offers pharmaceutical contract manufacturing services such as diagnostic services, API services, and pharmaceutical development. Also, through this segment, the company offers solutions such as clinical trial solutions, supporting services, global laboratories, panels and assays, and claraT mRNA Report.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • AbbVie Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Ltd.
  • Charles River Laboratories International Inc.
  • Cmic Holdings Co. Ltd.
  • Dalton Pharma Services
  • Dr Reddys Laboratories Ltd.
  • Grifols SA
  • Laboratory Corp. of America Holdings
  • Lonza Group Ltd.
  • Lupin Ltd.
  • Novotech Health Holdings
  • OPTIMAPHARM d.o.o.
  • Parexel International Corp.

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segments in the Pharmaceutical Contract Manufacturing Market?

The market share growth by the big pharmaceutical companies segment will be significant during the forecast period. Big pharmaceutical companies is a term for the world's largest publicly traded pharmaceutical companies. The largest pharmaceutical companies may also have divisions that produce medical equipment. These companies are usually larger than companies that focus on medical devices alone. 

Get a glance at the market contribution of various segments View the PDF Sample

The big pharmaceutical companies segment was valued at USD 52.73 billion in 2017 and continue to grow by 2021.  In this segmnet, pharmaceutical clients can extend their technical resources by outsourcing to a CMO without incurring more overhead. CMOs have become more significant in the pharmaceutical sector during the past 25 years. Moreover, the big pharmaceutical companies have also been prioritizing their efforts in their core competencies. Hence, they prefer not to use the existing tools, knowledge, and technology when creating the final dose of medications. Instead of producing the formulated drug to remain competitive in the market, pharmaceutical companies had to review their production techniques and R&D operations. This was due to growing competition and narrowing profit margins. Thus, such a partnership between big pharmaceutical companies and CMOs is expected to drive the growth of the global pharmaceutical contract manufacturing market through the big pharmaceutical companies segment during the forecast period.

Which are the Key Regions for the Pharmaceutical Contract Manufacturing Market?

For more insights on the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The pharmaceutical contract manufacturing market in North America is experiencing significant growth, driven by increasing demand for cost-effective and efficient drug manufacturing solutions. In recent years, there has been rapid growth in the number of new and innovative drugs entering the market. These drugs are often highly specialized and require specialized manufacturing processes that are not available in-house for pharmaceutical firms. This has led to an increasing dependence on CMOs that have the required expertise and facilities to manufacture these specialized drugs. Such factors will increase the market growth during the forecast period.

In 2020, COVID-19 adversely affected all countries in North America, especially the US. However, the pandemic positively impacted the pharmaceutical contract manufacturing market in North America. Thus, to meet the demand-supply gap with regards to pharmaceuticals in the region, the demand for pharmaceutical contract manufacturing increased significantly in 2020. This resulted in the significant market growth in 2020. The market is expected to register a positive growth rate during the forecast period, owing to the constant efforts to contain the spread of the disease. 

Segment Overview

The pharmaceutical contract manufacturing market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • End-User Outlook (USD Million, 2017 - 2027)
    • Big pharmaceutical companies
    • Small and medium-sized pharmaceutical companies
    • Generic pharmaceutical companies
  • Service Outlook (USD Million, 2017 - 2027)
    • API/bulk drug manufacturing
    • Final dosage form
    • Secondary packaging
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Australia
      • Argentina
      • Rest of the world

Parent Market Analysis

Technavio categorizes the global pharmaceutical contract manufacturing market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in the R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our market research report has extensively covered external factors influencing the parent market growth during the forecast period.

Pharmaceutical Contract Manufacturing Market Scope

Report Coverage

Details

Page number

159

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 7.81%

Market growth 2023-2027

USD 58 billion

Market structure

Fragmented

YoY growth 2022-2023(%)

7.01

Regional analysis

North America, Asia, Europe, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key countries

US, Germany, UK, China, and India

Competitive landscape

 Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Almac Group Ltd., Baxter International Inc., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Charles River Laboratories International Inc., Cmic Holdings Co. Ltd., Dalton Pharma Services, Dr Reddys Laboratories Ltd., Grifols SA, Laboratory Corp. of America Holdings, Lonza Group Ltd., Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Syneos Health Inc., and Thermo Fisher Scientific Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View the PDF sample

What are the Key Data Covered in this Pharmaceutical Contract Manufacturing Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the pharmaceutical contract manufacturing market between 2023 and 2027
  • Precise estimation of the size of the pharmaceutical contract manufacturing market size and its contribution of the market in focus to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Asia, Europe, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of pharmaceutical contract manufacturing market vendors

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Service
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global pharmaceutical contract manufacturing market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global pharmaceutical contract manufacturing market 2017 - 2021 ($ billion)
    • 4.2 End-user Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – End-user Segment 2017 - 2021 ($ billion)
    • 4.3 Service Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Service Segment 2017 - 2021 ($ billion)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by End-user

    • 6.1 Market segments
      • Exhibit 30: Chart on End-user - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on End-user - Market share 2022-2027 (%)
    • 6.2 Comparison by End-user
      • Exhibit 32: Chart on Comparison by End-user
      • Exhibit 33: Data Table on Comparison by End-user
    • 6.3 Big pharmaceutical companies - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Big pharmaceutical companies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 35: Data Table on Big pharmaceutical companies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 36: Chart on Big pharmaceutical companies - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Big pharmaceutical companies - Year-over-year growth 2022-2027 (%)
    • 6.4 Small and medium-sized pharmaceutical companies - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Small and medium-sized pharmaceutical companies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 39: Data Table on Small and medium-sized pharmaceutical companies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 40: Chart on Small and medium-sized pharmaceutical companies - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Small and medium-sized pharmaceutical companies - Year-over-year growth 2022-2027 (%)
    • 6.5 Generic pharmaceutical companies - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Generic pharmaceutical companies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 43: Data Table on Generic pharmaceutical companies - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 44: Chart on Generic pharmaceutical companies - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Generic pharmaceutical companies - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by End-user
      • Exhibit 46: Market opportunity by End-user ($ billion)
      • Exhibit 47: Data Table on Market opportunity by End-user ($ billion)

    7 Market Segmentation by Service

    • 7.1 Market segments
      • Exhibit 48: Chart on Service - Market share 2022-2027 (%)
      • Exhibit 49: Data Table on Service - Market share 2022-2027 (%)
    • 7.2 Comparison by Service
      • Exhibit 50: Chart on Comparison by Service
      • Exhibit 51: Data Table on Comparison by Service
    • 7.3 API/bulk drug manufacturing - Market size and forecast 2022-2027
      • Exhibit 52: Chart on API/bulk drug manufacturing - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 53: Data Table on API/bulk drug manufacturing - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 54: Chart on API/bulk drug manufacturing - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on API/bulk drug manufacturing - Year-over-year growth 2022-2027 (%)
    • 7.4 Final dosage form - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Final dosage form - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 57: Data Table on Final dosage form - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 58: Chart on Final dosage form - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Final dosage form - Year-over-year growth 2022-2027 (%)
    • 7.5 Secondary packaging - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Secondary packaging - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 61: Data Table on Secondary packaging - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 62: Chart on Secondary packaging - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Secondary packaging - Year-over-year growth 2022-2027 (%)
    • 7.6 Market opportunity by Service
      • Exhibit 64: Market opportunity by Service ($ billion)
      • Exhibit 65: Data Table on Market opportunity by Service ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Asia - Market size and forecast 2022-2027
      • Exhibit 75: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 76: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 77: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.5 Europe - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 China - Market size and forecast 2022-2027
      • Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.9 India - Market size and forecast 2022-2027
      • Exhibit 95: Chart on India - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 96: Data Table on India - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 97: Chart on India - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on India - Year-over-year growth 2022-2027 (%)
    • 9.10 Germany - Market size and forecast 2022-2027
      • Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.11 UK - Market size and forecast 2022-2027
      • Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
      • Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ billion)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 Almac Group Ltd.
              • Exhibit 115: Almac Group Ltd. - Overview
              • Exhibit 116: Almac Group Ltd. - Product / Service
              • Exhibit 117: Almac Group Ltd. - Key offerings
            • 12.4 Boehringer Ingelheim International GmbH
              • Exhibit 118: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 119: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 120: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 121: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 122: Boehringer Ingelheim International GmbH - Segment focus
            • 12.5 Cadila Pharmaceuticals Ltd.
              • Exhibit 123: Cadila Pharmaceuticals Ltd. - Overview
              • Exhibit 124: Cadila Pharmaceuticals Ltd. - Product / Service
              • Exhibit 125: Cadila Pharmaceuticals Ltd. - Key offerings
            • 12.6 Charles River Laboratories International Inc.
              • Exhibit 126: Charles River Laboratories International Inc. - Overview
              • Exhibit 127: Charles River Laboratories International Inc. - Business segments
              • Exhibit 128: Charles River Laboratories International Inc. - Key news
              • Exhibit 129: Charles River Laboratories International Inc. - Key offerings
              • Exhibit 130: Charles River Laboratories International Inc. - Segment focus
            • 12.7 Cmic Holdings Co. Ltd.
              • Exhibit 131: Cmic Holdings Co. Ltd. - Overview
              • Exhibit 132: Cmic Holdings Co. Ltd. - Business segments
              • Exhibit 133: Cmic Holdings Co. Ltd. - Key offerings
              • Exhibit 134: Cmic Holdings Co. Ltd. - Segment focus
            • 12.8 Dr Reddys Laboratories Ltd.
              • Exhibit 135: Dr Reddys Laboratories Ltd. - Overview
              • Exhibit 136: Dr Reddys Laboratories Ltd. - Business segments
              • Exhibit 137: Dr Reddys Laboratories Ltd. - Key offerings
              • Exhibit 138: Dr Reddys Laboratories Ltd. - Segment focus
            • 12.9 Laboratory Corp. of America Holdings
              • Exhibit 139: Laboratory Corp. of America Holdings - Overview
              • Exhibit 140: Laboratory Corp. of America Holdings - Business segments
              • Exhibit 141: Laboratory Corp. of America Holdings - Key news
              • Exhibit 142: Laboratory Corp. of America Holdings - Key offerings
              • Exhibit 143: Laboratory Corp. of America Holdings - Segment focus
            • 12.10 Lonza Group Ltd.
              • Exhibit 144: Lonza Group Ltd. - Overview
              • Exhibit 145: Lonza Group Ltd. - Business segments
              • Exhibit 146: Lonza Group Ltd. - Key news
              • Exhibit 147: Lonza Group Ltd. - Key offerings
              • Exhibit 148: Lonza Group Ltd. - Segment focus
            • 12.11 Lupin Ltd.
              • Exhibit 149: Lupin Ltd. - Overview
              • Exhibit 150: Lupin Ltd. - Product / Service
              • Exhibit 151: Lupin Ltd. - Key news
              • Exhibit 152: Lupin Ltd. - Key offerings
            • 12.12 OPTIMAPHARM d.o.o.
              • Exhibit 153: OPTIMAPHARM d.o.o. - Overview
              • Exhibit 154: OPTIMAPHARM d.o.o. - Product / Service
              • Exhibit 155: OPTIMAPHARM d.o.o. - Key offerings
            • 12.13 Parexel International Corp.
              • Exhibit 156: Parexel International Corp. - Overview
              • Exhibit 157: Parexel International Corp. - Product / Service
              • Exhibit 158: Parexel International Corp. - Key news
              • Exhibit 159: Parexel International Corp. - Key offerings
            • 12.14 PCI Pharma Services
              • Exhibit 160: PCI Pharma Services - Overview
              • Exhibit 161: PCI Pharma Services - Product / Service
              • Exhibit 162: PCI Pharma Services - Key offerings
            • 12.15 Recipharm AB
              • Exhibit 163: Recipharm AB - Overview
              • Exhibit 164: Recipharm AB - Business segments
              • Exhibit 165: Recipharm AB - Key offerings
              • Exhibit 166: Recipharm AB - Segment focus
            • 12.16 Syneos Health Inc.
              • Exhibit 167: Syneos Health Inc. - Overview
              • Exhibit 168: Syneos Health Inc. - Business segments
              • Exhibit 169: Syneos Health Inc. - Key offerings
              • Exhibit 170: Syneos Health Inc. - Segment focus
            • 12.17 Thermo Fisher Scientific Inc.
              • Exhibit 171: Thermo Fisher Scientific Inc. - Overview
              • Exhibit 172: Thermo Fisher Scientific Inc. - Business segments
              • Exhibit 173: Thermo Fisher Scientific Inc. - Key news
              • Exhibit 174: Thermo Fisher Scientific Inc. - Key offerings
              • Exhibit 175: Thermo Fisher Scientific Inc. - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 176: Inclusions checklist
                • Exhibit 177: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 178: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 179: Research methodology
                • Exhibit 180: Validation techniques employed for market sizing
                • Exhibit 181: Information sources
              • 13.5 List of abbreviations
                • Exhibit 182: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              pharmaceutical contract manufacturing market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis